Cargando…

Patients with precursor disease exhibit similar psychological distress and mental HRQOL as patients with active myeloma

Detalles Bibliográficos
Autores principales:	Maatouk, Imad, He, Susanne, Hummel, Manuela, Hemmer, Stefan, Hillengass, Michaela, Goldschmidt, Hartmut, Hartmann, Mechthild, Herzog, Wolfgang, Hillengass, Jens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341083/ https://www.ncbi.nlm.nih.gov/pubmed/30664623 http://dx.doi.org/10.1038/s41408-019-0172-1

Ejemplares similares

Association of resilience with health-related quality of life and depression in multiple myeloma and its precursors: results of a German cross-sectional study
por: Maatouk, Imad, et al.
Publicado: (2018)

Physical Activity in Multiple Myeloma: A Review of the Current Literature
por: Hillengass, Michaela, et al.
Publicado: (2023)

Body fat composition as predictive factor for treatment response in patients with newly diagnosed multiple myeloma – subgroup analysis of the prospective GMMG MM5 trial
por: GroΔ, Jonathan P., et al.
Publicado: (2017)

Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation
por: Mosebach, Jennifer, et al.
Publicado: (2018)

High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting
por: Lisenko, Katharina, et al.
Publicado: (2017)

Analysis of long‐term survival in multiple myeloma after first‐line autologous stem cell transplantation: impact of clinical risk factors and sustained response
por: Lehners, Nicola, et al.
Publicado: (2017)

Physical activity-related health competence and symptom burden for exercise prescription in patients with multiple myeloma: a latent profile analysis
por: Kuehl, Rea, et al.
Publicado: (2023)

A systematic classification of death causes in multiple myeloma
por: Mai, Elias K., et al.
Publicado: (2018)

Future Directions in Maintenance Therapy in Multiple Myeloma
por: Holstein, Sarah A., et al.
Publicado: (2021)

miRNAs in multiple myeloma – a survival relevant complex regulator of gene expression
por: Seckinger, Anja, et al.
Publicado: (2015)

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma
por: Baertsch, Marc-Andrea, et al.
Publicado: (2021)

Comparison of functional imaging in multiple myeloma patients: Indication for hybrid-imaging with PET/MRI?
por: Mosebach, J, et al.
Publicado: (2015)

Spatial Distribution of Focal Lesions in Whole-Body MRI and Influence of MRI Protocol on Staging in Patients with Smoldering Multiple Myeloma According to the New SLiM-CRAB-Criteria
por: Wennmann, Markus, et al.
Publicado: (2020)

Analyzing Longitudinal wb-MRI Data and Clinical Course in a Cohort of Former Smoldering Multiple Myeloma Patients: Connections between MRI Findings and Clinical Progression Patterns
por: Wennmann, Markus, et al.
Publicado: (2021)

Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group
por: Hillengass, J, et al.
Publicado: (2017)

Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation
por: Merz, Maximilian, et al.
Publicado: (2017)

Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients
por: Kriegsmann, Katharina, et al.
Publicado: (2019)

Impact, distress and HRQoL among Malaysian men and women with a mobility impairment
por: Misajon, RoseAnne, et al.
Publicado: (2006)

Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma
por: Viziteu, Elena, et al.
Publicado: (2016)

Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma
por: Merz, Maximilian, et al.
Publicado: (2019)

Characterization of multiple myeloma osseous lesions and diffuse infiltration pattern by 18F-FDG-PET/CT, static MRI and diffusion-weighted MR Imaging (DWI-MRI): a comparative multimodality imaging study
por: Mosebach, J, et al.
Publicado: (2014)

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma
por: Salwender, Hans, et al.
Publicado: (2019)

Genetic factors influencing the risk of multiple myeloma bone disease
por: Johnson, D C, et al.
Publicado: (2016)

Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma
por: Johnson, David C., et al.
Publicado: (2016)

Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee
por: Kumar, Shaji, et al.
Publicado: (2022)

Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis
por: Khandanpour, Cyrus, et al.
Publicado: (2021)

P959: CILTACABTAGENE AUTOLEUCEL IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY: CARTITUDE-2 BIOLOGICAL CORRELATIVE ANALYSES AND UPDATED CLINICAL DATA
por: Hillengass, J., et al.
Publicado: (2022)

Volumetry based biomarker speed of growth: Quantifying the change of total tumor volume in whole-body magnetic resonance imaging over time improves risk stratification of smoldering multiple myeloma patients
por: Wennmann, Markus, et al.
Publicado: (2018)

Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level
por: John, Lukas, et al.
Publicado: (2023)

Can post-treatment oral cancer patients’ concerns reflect their cancer characteristics, HRQoL, psychological distress level and satisfaction with consultation?
por: Aminnudin, Ainon Natrah, et al.
Publicado: (2020)

Withanolide D Exhibits Similar Cytostatic Effect in Drug-Resistant and Drug-Sensitive Multiple Myeloma Cells
por: Issa, Mark E., et al.
Publicado: (2017)

P08: CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY
por: Einsele, H, et al.
Publicado: (2022)

P831: NOVEL IMMUNOSUPPRESSIVE MYELOID POPULATIONS IN THE BONE MARROW (BM) AND OSTEOLYTIC LESIONS (OL) OF MULTIPLE MYELOMA (MM) PATIENTS
por: Hillengass, Jens, et al.
Publicado: (2023)

CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma—Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance
por: Seckinger, Anja, et al.
Publicado: (2018)

The challenges of classical galactosemia: HRQoL in pediatric and adult patients
por: Hermans, Merel E., et al.
Publicado: (2023)

Health–related quality of life (HRQOL) and migraine
por: Apolone, Giovanni, et al.
Publicado: (2001)

HRQOL after endoscopic transaxillary gasless hemithyroidectomy
por: Jasaitis, Kristijonas, et al.
Publicado: (2023)

Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma
por: Sachpekidis, Christos, et al.
Publicado: (2019)

IgE type multiple myeloma exhibits hypermutated phenotype and tumor reactive T cells
por: Kehl, Niklas, et al.
Publicado: (2022)

Imaging of treatment response and minimal residual disease in multiple myeloma: state of the art WB-MRI and PET/CT
por: Lecouvet, Frederic E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1cnlbebvl6p1t3eraf3ntuklcb